VF Test for Prediction of Extremely PTB After Cerclage
Status: | Not yet recruiting |
---|---|
Conditions: | Infectious Disease, Women's Studies |
Therapuetic Areas: | Immunology / Infectious Diseases, Reproductive |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/24/2018 |
Start Date: | April 2018 |
End Date: | April 2019 |
Contact: | Kimberly Maurel |
Email: | kimberly_maurel@mednax.com |
Phone: | 714-593-9171 |
Vaginal Fluid (VF) Test VF-Test™ for Prediction of Extremely Preterm Birth After Exam-Indicated Cerclage Protocol for Prospective, Multicenter, Cohort Clinical Trial
The purpose of this research study is to determine if a vaginal fluid (VF) test can predict
very early preterm birth in patients who are scheduled to have an exam indicated cerclage for
severe cervical shortening.
Prior to participants undergoing a scheduled amniocentesis two swabs to collect vaginal
secretions for the VF tests will be done. During the amniocentesis your doctor will remove
amniotic fluid as part of the routine clinical care. From that fluid sample, the study will
use less than a quarter teaspoon for the amniotic fluid study test (AF test). Data regarding
maternal and birth outcomes will be collected by medical record review.
very early preterm birth in patients who are scheduled to have an exam indicated cerclage for
severe cervical shortening.
Prior to participants undergoing a scheduled amniocentesis two swabs to collect vaginal
secretions for the VF tests will be done. During the amniocentesis your doctor will remove
amniotic fluid as part of the routine clinical care. From that fluid sample, the study will
use less than a quarter teaspoon for the amniotic fluid study test (AF test). Data regarding
maternal and birth outcomes will be collected by medical record review.
The purpose of this research study is to determine if a vaginal fluid (VF) test can predict
very early preterm birth in patients who are scheduled to have an exam indicated cerclage for
severe cervical shortening.
Prior to participants undergoing a scheduled amniocentesis, an ultrasound will be done to
confirm cervical length and dilation. During a separate sterile speculum exam, the physician
will use two swabs to collect vaginal secretions for the VF test. During the amniocentesis
the doctor will remove approximately 2 teaspoon of amniotic fluid as part of your standard
clinical care. From that fluid sample, the study will use less than a quarter teaspoon for a
amniotic fluid study test (AF test). Data regarding maternal and birth outcomes will be
collected by medical record review.
The vaginal fluid (VF) sample collection will take approximately 15 minutes to do. The total
time in the study is about seven and a half months (from the time the patient consents until
4 weeks after delivery). The only study procedure the patient will experience during her
study participation is the collection of the vaginal fluid specimens.
very early preterm birth in patients who are scheduled to have an exam indicated cerclage for
severe cervical shortening.
Prior to participants undergoing a scheduled amniocentesis, an ultrasound will be done to
confirm cervical length and dilation. During a separate sterile speculum exam, the physician
will use two swabs to collect vaginal secretions for the VF test. During the amniocentesis
the doctor will remove approximately 2 teaspoon of amniotic fluid as part of your standard
clinical care. From that fluid sample, the study will use less than a quarter teaspoon for a
amniotic fluid study test (AF test). Data regarding maternal and birth outcomes will be
collected by medical record review.
The vaginal fluid (VF) sample collection will take approximately 15 minutes to do. The total
time in the study is about seven and a half months (from the time the patient consents until
4 weeks after delivery). The only study procedure the patient will experience during her
study participation is the collection of the vaginal fluid specimens.
Inclusion Criteria:
- Participant age 18 years or older
- Gestational age between 16w0d to 25w6d
- Singleton fetus with no apparent major anomalies on ultrasound exam
- Sonographically absent cervical length and/or sterile digital exam of 2cm or greater
dilation
- Exam-indicated cervical cerclage has been recommended by clinician and patient agrees
to proceed with cervical cerclage placement
- Decision has been made by provider to perform pre-cerclage amniocentesis to rule-out
infection, with the understanding that cerclage is contraindicated if findings
indicate probable or definitive infection, and patient agrees.
Exclusion Criteria:
- Planned termination of pregnancy
- Clinical features consistent with placental abruption or chorioamnionitis
- Need for immediate delivery based on maternal or fetal issues
- Fetus with ultrasound-determined major congenital anomalies
- Multiple gestation
- Rupture of membranes
- Patient does not give consent to participate in this study
We found this trial at
6
sites
Mesa, Arizona 85202
Principal Investigator: Christopher K Huls, MD
Phone: 602-257-8118
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Richard Porreco, MD
Phone: 303-860-9990
Click here to add this to my saved trials
Long Beach, California 90801
Principal Investigator: Michael Nageotte, MD
Phone: 562-933-2730
Click here to add this to my saved trials
Phoenix, Arizona 85006
Principal Investigator: Christopher K Huls, MD
Phone: 602-257-8118
Click here to add this to my saved trials
San Jose, California 95124
Principal Investigator: Andrew Combs, MD
Phone: 408-371-7111
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Jeroen Vanderhoeven, MD
Phone: 206-386-2101
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
Click here to add this to my saved trials